biostudies-literatureLiyasova MMolly and David Bloom ChairRapid Novor, IncCanadian Cancer Society Research Institute5028-5037https://www.ebi.ac.uk/biostudies/studies/S-EPMC9401514biostudies-literatureUnknown27(18)<h4>Purpose</h4>M-protein is a well-established biomarker used for multiple myeloma monitoring. Current improvements in multiple myeloma treatment created the need to monitor minimal residual disease (MRD) with high sensitivity. Measuring residual levels of M-protein in serum by MS was established as a sensitive assay for disease monitoring. In this study we evaluated the performance of EasyM-a noninvasive, sensitive, MS-based assay for M-protein monitoring.<h4>Experimental design</h4>Twenty-six patients enrolled in MCRN-001 clinical trial of two high-dose alkylating agents as conditioning followed by lenalidomide maintenance were selected for the study. All selected patients achieved complete responses (CR) during treatment, whereas five experienced progressive disease on study. The M-proClinical cancer research : an official journal of the American Association for Cancer ResearchA Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM).PMC9401514704269Liyasova MPiza GYang LTrudel SLiu QAtenafu EGTaylor PReece DMa BMcDonald ZGorospe KYao CXu XfalseA Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM).<h4>Purpose</h4>M-protein is a well-established biomarker used for multiple myeloma monitoring. Current improvements in multiple myeloma treatment created the need to monitor minimal residual disease (MRD) with high sensitivity. Measuring residual levels of M-protein in serum by MS was established as a sensitive assay for disease monitoring. In this study we evaluated the performance of EasyM-a noninvasive, sensitive, MS-based assay for M-protein monitoring.<h4>Experimental design</h4>Twenty-six patients enrolled in MCRN-001 clinical trial of two high-dose alkylating agents as conditioning followed by lenalidomide maintenance were selected for the study. All selected patients achieved complete responses (CR) during treatment, whereas five experienced progressive disease on study. The M-pro2021-01-01T00:00:00Z2021 Sep2026-05-10T06:44:17.571Z2025-04-04T13:08:54.485ZS-EPMC94015143421068310.1158/1078-0432.CCR-21-0649